Treatments for macular degeneration: summarising evidence using network meta-analysis
- Laboratorio SIFO di Farmacoeconomia, Area Vasta Centro Toscana, ESTAV, Prato, Italy
- Correspondence to Dr Andrea Messori, Laboratorio SIFO di Farmacoeconomia, c/o Area Vasta Centro Toscana, Regional Health System, Via Guimaraes 9-11, 59100 Prato, Italy;
Contributors All authors contributed equally to this manuscript.
- Accepted 18 May 2011
- Published Online First 16 June 2011
- clinical trial
In studying treatments for age-related macular degeneration (AMD), randomised controlled trials have typically used placebo or verteporfin in the control group.1 2 Hence, information on direct head-to-head comparisons between the newest agents is still needed.
Network meta-analysis (NMA) is a tool that summarises the information on comparative effectiveness when three or more treatments are proposed for the same clinical indication.3 4 NMA includes both direct comparisons (based on real trials) and indirect comparisons (based on statistical testing in the absence of a real head-to-head trial). The main advantage of NMA lies in its communicative value5; another advantage is that it overcomes one …